NIFEDIPINE ER TABLET (EXTENDED-RELEASE)
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
27-02-2019
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
NIFEDIPINE
Tilgængelig fra:
PRO DOC LIMITEE
ATC-kode:
C08CA05
INN (International Name):
NIFEDIPINE
Dosering:
60MG
Lægemiddelform:
TABLET (EXTENDED-RELEASE)
Sammensætning:
NIFEDIPINE 60MG
Indgivelsesvej:
ORAL
Enheder i pakken:
30/100
Recept type:
Prescription
Terapeutisk område:
DIHYDROPYRIDINES
Produkt oversigt:
Active ingredient group (AIG) number: 0115253005; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2014-03-18
Produktets egenskaber
PRODUCT MONOGRAPH
PR
NIFEDIPINE ER
Nifedipine Extended-Release Tablets, House Standard
20 mg, 30 mg and 60 mg Nifedipine
Antianginal/Antihypertensive Agent
PRO DOC LTÉE
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Date of Revision:
February 27, 2019
Submission Control No.: 224326
_ _
_NIFEDIPINE ER Product Monograph _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
CLINICAL TRIALS
..........................................................................................................25
DETAILED PHARMACOLOGY
....................
Læs hele dokumentet
